ASPirin in Reducing Events in the Elderly (ASPREE)

ASPREE is a randomized, double-blind, placebo-controlled study with the purpose of measuring aspirin's capacity to prolong a life free of functional disability—induced by dementia, cancer, and cardiovascular events—in an aging population. The ASPREE study will enroll 6,500 healthy individuals over age 70 in the US and another 12,500 in Australia. Enrollment at the University of Iowa is currently closed (two hundred of the participants were enrolled at the University of Iowa). 

For more information, visit www.aspree.org

For more information, contact:

Michael Ernst, PharmD 
319-384-7756 
michael-ernst@uiowa.edu